A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo

Biochemical and Biophysical Research Communications

Volumn 299, Issue 5, 2002, Pages 903-909

  Kuriyama, Kohji ^a,b   Higuchi, Chikahisa ^a,b   Tanaka, Keiichi ^c   Yoshikawa, Hideki ^b   Itoh, Kazuyuki ^a  

^a Osaka Medical Center and Cancer and Cardiovascular Diseases   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Bone morphogenetic protein; MC3T3 E1; Osteoblast; Osterix; ST2; T 614

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; CALCIUM; IGURATIMOD; OSTERIX; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; BONE METABOLISM; CELL ASSAY; CELL DIFFERENTIATION; CELL LINE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MINERALIZATION; MOUSE; NONHUMAN; NORTHERN BLOTTING; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

ALKALINE PHOSPHATASE; ANIMALS; ANTIRHEUMATIC AGENTS; BENZOPYRANS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; MICE; NEOPLASM PROTEINS; OSTEOBLASTS; OSTEOCALCIN; OSTEOGENESIS; RNA, MESSENGER; STROMAL CELLS; SULFONAMIDES; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0036921467     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(02)02754-7     Document Type: Article

References (27)

1. A. Erlebacher, E.H. Filvaroff, S.E. Gitelman, R. Derynck, Toward a molecular understanding of skeletal development, Cell 80 (1995) 371-378.
2. D.E. Hughes, B.R. MacDonald, R.G. Russell, M. Gowen, Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow, J. Clin. Invest. 83 (1989) 1930-1935.
3. P.J. Bekker, D. Holloway, A. Nakanishi, M. Arrighi, R.T. Leese, C.R. Dunstan, The effect of a single dose of osteoprotegerin in postmenopausal women, J. Bone Miner. Res. 16 (2001) 348-360.
4. G. Mundy, R. Garrett, S. Harris, J. Chan, D. Chen, G. Rossini, B. Boyce, M. Zhao, G. Gutierrez, Stimulation of bone formation in vitro and in rodents by statins, Science 286 (1999) 1946-1949.
5. S. Wakabayashi, T. Tsutsumimoto, S. Kawasaki, T. Kinoshita, H. Horiuchi, K. Takaoka, Involvement of phosphodiesterase isozymes in osteoblastic differentiation, J. Bone Miner. Res. 17 (2002) 249-256.
6. C. Higuchi, A. Myoui, N. Hashimoto, K. Kuriyama, K. Yoshioka, H. Yoshikawa, K. Itoh, Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of extracellular matrix, J. Bone Miner. Res. 17 (2002) 1785-1794.
7. Y. Aikawa, M. Yamamoto, T. Yamamoto, K. Morimoto, K. Tanaka, An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation, Inflamm. Res. 51 (2002) 188-194.
8. K. Tanaka, Y. Aikawa, H. Kawasaki, K. Asaoka, T. Inaba, C. Yoshida, Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: Inhibitory effect on the production of interleukin-1 and interleukin-6, J. Pharmacobiodyn. 15 (1992) 649-655.
9. M. Kohno, Y. Aikawa, Y. Tsubouchi, A. Hashiramoto, R. Yamada, Y. Kawahito, K. Inoue, Y. Kusaka, M. Kondo, H. Sano, Inhibitory effect of T-614 on tumor necrosis factor-α induced cytokine production and nuclear factor-κB activation in cultured human synovial cells, J. Rheumatol. 28 (2001) 2591-2596.
10. A. Kawakami, M. Tsuboi, S. Urayama, N. Matsuoka, S. Yamasaki, A. Hida, T. Aoyagi, I. Furuichi, T. Nakashima, K. Migita, Y. Kawabe, M. Nakashima, T. Origuchi, K. Eguchi, Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells, J. Lab. Clin. Med. 133 (1999) 566-574.
11. K. Tanaka, T. Shimotori, Y. Taniguchi, M. Eguchi, C. Abe, Pharmacological studies on T-614, a novel antiinflammatory agent: Effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/I mice, Int. J. Immunother. 9 (1993) 69-78.
12. E. Otsuka, A. Yamaguchi, S. Hirose, H. Hagiwara, Characterization of osteoblastic differentiation of stromal cell line ST2 that is induced by ascorbic acid, Am. J. Physiol. 277 (1999) C132-C138.
13. L.D. Quarles, D.A. Yohay, L.W. Lever, R. Caton, R.J. Wenstrup, Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: An in vitro model of osteoblast development, J. Bone Miner. Res. 7 (1992) 683-692.
14. H. Horiuchi, N. Saito, T. Kinoshita, S. Wakabayashi, T. Tsutsumimoto, K. Takaoka, Enhancement of bone morphogenetic protein-2-induced new bone formation in mice by the phosphodiesterase inhibitor pentoxifylline, Bone 28 (2001) 290-294.
15. T. Komori, H. Yagi, S. Nomura, A. Yamaguchi, K. Sasaki, K. Deguchi, Y. Shimizu, R.T. Bronson, Y.H. Gao, M. Inada, M. Sato, R. Okamoto, Y. Kitamura, S. Yoshiki, T. Kishimoto, Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts, Cell 89 (1997) 755-764.
16. K. Nakashima, X. Zhou, G. Kunkel, Z. Zhang, J.M. Deng, R.R. Behringer, B. de Crombrugghe, The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation, Cell 108 (2002) 17-29.
17. P. Ducy, R. Zhang, V. Geoffroy, A.L. Ridall, G. Karsenty, Osf2/Cbfa1: A transcriptional activator of osteoblast differentiation, Cell 89 (1997) 747-754.
18. K. Miyazono, Signal transduction by bone morphogenetic protein receptors: Functional roles of Smad proteins, Bone 25 (1999) 91-93.
19. A. Hollnagel, V. Oehlmann, J. Heymer, U. Ruther, A. Nordheim, Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells, J. Biol. Chem. 274 (1999) 19838-19845.
20. G. Franzoso, L. Carlson, L. Xing, L. Poljak, E.W. Shores, K.D. Brown, A. Leonardi, T. Tran, B.F. Boyce, U. Siebenlist, Requirement for NF-κB in osteoclast and B-cell development, Genes Dev. 11 (1997) 3482-3496.
21. V. Iotsova, J. Caamano, J. Loy, Y. Yang, A. Lewin, R. Bravo, Osteopetrosis in mice lacking NF-κB1 and NF-κB2, Nat. Med. 3 (1997) 1285-1289.
22. E. Kopp, S. Ghosh, Inhibition of NF-κB by sodium salicylate and aspirin, Science 265 (1994) 956-959.
23. S.D. Isaacs, X. Fan, D. Fan, H. Gewant, T.C. Murphy, P. Farmer, W.R. Taylor, M.S. Nanes, J. Rubin, Role of NFκB in the regulation of macrophage colony stimulating factor by tumor necrosis factor-α in ST2 bone stromal cells, J. Cell. Physiol. 179 (1999) 193-200.
24. K. Tanaka, H. Kawasaki, K. Kurata, Y. Aikawa, Y. Tsukamoto, T. Inaba, T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts, Jpn. J. Pharmacol. 67 (1995) 305-314.
25. D. Chikazu, X. Li, H. Kawaguchi, Y. Sakuma, O.S. Voznesensky, D.J. Adams, M. Xu, K. Hoshio, V. Katavic, H.R. Herschman, L.G. Raisz, C.C. Pilbeam, Related, bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: Role in effects of bone morphogenetic protein 2 in vitro and in vivo, J. Bone Miner. Res. 17 (2002) 1430-1440.
26. X. Zhang, E.M. Schwarz, D.A. Young, J.E. Puzas, R.N. Rosier, R.J. O'Keefe, Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair, J. Clin. Invest. 109 (2002) 1405-1415.
27. A.M. Simon, M.B. Manigrasso, J.P. O'Connor, Cyclo-oxygenase 2 function is essential for bone fracture healing, J. Bone Miner. Res. 17 (2002) 963-976.